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piperazineAbstract Piperazine-related drugs are sold as party pills in the form of tablets, capsules, liquids or
powders. These party pills can contain several piperazine derivatives, or even a mixture of pipera-
zines and amphetamine derivatives. This paper describes a screening method using a gas chroma-
tography–mass spectrometry technique allowing the separation and the identiﬁcation of active
components within these mixtures by a combined silylation and acylation derivatization procedure.
The studied substances–namely: 1-benzylpiperazine (BZP), 1-(3,4-methylenedioxyben-zyl)pipera-
zine (MDBP), 1-(3-triﬂuoromethylphenyl)piperazine (TFMPP), 1-(3-chlorophenyl) piperazine
(mCPP), 1-(4-methoxyphenyl) piperazine (MeOPP), amphetamine, methamphetamine, ephedrine,
pseudoephedrine, 3,4-methylenedioxy-N-methamphetamine (MDMA), 3,4-methylenedi-oxyam-
phetamine (MDA), 3,4-methylenedioxy-N-ethylamphetamine (MDEA) and N-methyl-1,3-ben-
zodioxolylbutanamine (MBDB)–are separated.
ª 2014 The International Association of Law and Forensic Sciences (IALFS). Production and hosting by
Elsevier B.V. All rights reserved.1. Introduction
Synthetic drugs are among the most commonly abused drugs
in the world. Some are derived from phenylethylamine, as is
3,4-methylenedioxymethamphetamine (MDMA). However,ll rights
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zines) have appeared on the market to bypass the law.
Chemically, piperazines are synthesized from the same
piperazine moiety and they can be classiﬁed into two classes:
benzylpiperazines, such as 1-benzylpiperazine (BZP) and its
methylenedioxy analog 1-(3,4-methylenedioxybenzyl) pipera-
zine (MDBP) and phenylpiperazines, such as 1-(3-triﬂuoro-
methylphenyl) piperazine (TFMPP), 1-(3-chlorophenyl)
piperazine (mCPP) and 1-(4-methoxyphenyl) piperazine
(MeOPP).
Piperazine-like compounds have spread around the world;
according to Kovaleva et al., it was estimated that approxi-
mately 823,000 tablets of mCPP have been seized in 2008 in
the European Union.1 In the Netherlands, the number of
mCPP tablets seized alone or in combination with MDMA
increased signiﬁcantly.2 A recent survey in the United King-
dom found that piperazines are among the most common
active drugs in tablet form purchased from internet supplier
sites.3 These drugs have also been seized in New Zealand,4,5
Japan,6 Brazil7 and many other countries such as Bulgaria,
Sweden and South Africa.8
Commonly, piperazines are sold as party pills in the form of
tablets, capsules, liquids or powders on the black drug-market
and in so-called head shops or over the internet under the
names of ‘‘Rapture,’’ ‘‘Frenzy,’’ ‘‘Bliss,’’ ‘‘Charge,’’ ‘‘Her-
bal ecstasy,’’ ‘‘A2,’’ ‘‘Legal X’’ and ‘‘Legal E’’.9,10 They are
also found in tablets sold as ecstasy or amphetamines.9–17
Generally, the party pills contain piperazine blends. Besides
the most prevalent mixture of BZP with TFMPP,18,19 there are
also combinations of up to four different piperazines that are
sold to consumers as ‘‘party pills’’ or ‘‘P.E.P. pills’’ called
X4.20–24 Furthermore, a large number of seized tablets con-
taining mixtures of piperazine and amphetamine type stimu-
lants (ATS) have been reported.2,11–13,25–35
Several methods related to the identiﬁcation of piperazine-
like compounds in both seized and biological samples have
been reported,12,36–42 but an identiﬁcation method for amphet-
amine-piperazine mixtures, as encountered in a large number
of seizures, has not been described yet. The aim of this work
is therefore to develop a qualitative method using a gas chro-
matography-mass spectrometry technique which allows the
separation and the identiﬁcation of a mixture composed of
piperazines and ATS. For the quantitative method, it was cho-
sen to extend to piperazines an HPLC/DAD method, previ-
ously implemented for the quantiﬁcation of amphetamine-
type stimulants.43 The method was validated following an
approach using accuracy proﬁles based on b-expectation toler-
ance intervals for total error measurement.
2. Experimental
2.1. Reagents and standards
Reference compounds 1-(4-methoxyphenyl)piperazine (meopp)
dihydrochloride, 1-(4-methylphenyl)piperazine (ptp) dihydro-
chloride (internal standard), 1-(3-chlorophenyl)piperazine
(mcpp) hydrochloride, 1-(3-triﬂuoromethylphenyl)piperazine
(TFMPP) hydrochloride, 1-(3,4-methylenedioxybenzyl) pipera-
zine (MDBP) free base and 1-benzylpiperazine (BZP) were pur-
chased from Lancaster (Frankfurt, Germany). Analytical
standards of amphetamine, methamphetamine, ephedrine,pseudoephedrine, 3,4-methylenedioxy-N-methamphet-amine
(MDMA), 3,4-methylenedioxyamphetamine (MDA), 3,4-meth-
ylenedioxy-N-ethylamphetamine (MDEA) and N-methyl-1,3-
benzodioxolylbutanamine (MBDB) were purchased from Pro-
mochem (Wesel, Germany) as 1 mg/ml methanolic solutions.
Lactose was purchased from Fluka (Steinheim, Germany)
Heptaﬂuorobutyric anhydride (HFBA) and the silylation
reagent SilPrep were purchased from Alltech (Templemars,
France).
Methanol and acetonitrile (HPLC grade), n-hexane, potas-
sium dihydrogenphosphate (KH2PO4) and 85% ortho-phos-
phoric acid (analytical grade) were purchased from VWR
Prolabo (Fontenay-sous-Bois, France).
2.2. Calibrators and specimen preparation for GC/MS
qualitative analysis
Stock solutions of BZP, MBDP, mCPP, TFMPP and MeOPP
at a concentration of 2 mg/mL were prepared in methanol.
Working solutions of amphetamine-piperazine mixtures were
obtained by dilution in methanol.
All these solutionswere storedprotected from light at +5 C.
GC/MS analyses of the piperazine derivative mixture were
performed ﬁrst without derivatization at a concentration of
2 mg/mL, and then carried out after silylation and acylation
at a concentration of 10 mg/L. The silylation was performed
by adding 125 lL of SilPrep reagent to the evaporation res-
idue of 125 lL of each 10 mg/L working solution. The acyla-
tion was performed by adding 25 lL of HFBA reagent to
the evaporation residue of 300 lL of each 10 mg/L working
solution, followed by 300 lL of hexane and 1 mL of 0.02 M
potassium dihydrogen phosphate neutralizing solution. The
mixture was centrifuged for 1 min at 302 g and the organic
layer analyzed by GCMS.
The combined silylation–acylation derivatization procedure
was performed by adding 100 lL of the upper layers of each
acylated solution to its silylated counterpart.
2.3. Calibrators and validation standards preparation for the
validation of the HPLC/DAD quantiﬁcation method
Stock solutions of amphetamines, piperazines, internal stan-
dard and lactose at a concentration of 1 mg/mL were prepared
in methanol/water 50:50 (v/v).
Subsequent working solutions were prepared by proper
dilutions of the stock solutions with methanol/water 50:50
(v/v). The calibration standard solutions were prepared from
a different stock solution batch than that of the validation
standards.
Each operator prepared his own piperazine derivative mix
calibration standards, by dilution of the stock solutions with
methanol/water 50:50 (v/v) and 1 mg/mL internal standard
(pTP) to obtain eight calibration standards of 2, 10, 20, 30,
40, 50, 80 and 100 mg/L (m= 8). This operation was repeated
on three different days, by three different operators.
The validation standards were prepared once and analyzed
by each operator, with the calibration standards the operator
had prepared. For routine work, tablets from the seized mate-
rial were crushed in a mortar and a pestle and 50 mg of the
resulting powder were weighed on a precision scale
(e= 104 g) and subsequently dissolved in 50 mL of the
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on vortex, sonicated for 15 min and centrifuged for 1 min at
302 g. One hundred (100) lL of the prepared solution was
added to 100 lL of internal standard solution (1 mg/mL),
and then ﬁlled up to 1 mL volume by adding methanol/water
50:50 (v/v) mixture solvent. Lactose is a substance known to
be present in tablets (ﬁlling agent). Lactose has been added
to the validation standards in order to mimic the matrix effect
that can potentially be seen in the analysis of tablets. This is
why the stock solutions were mixed with the lactose solution
and 1 mg/mL internal standard (pTP) to obtain 11 validation
standards of 2, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 mg/
L (m= 11).
Four replications of each validation standard were per-
formed (n= 4). This operation was repeated on three different
days (p= 3), by three different operators.
2.4. Validation software and principles of the quantiﬁcation
method
In accordance with ISO/CEI 17025:2005 and the guidelines of
the French standard NF V 03–110,44 the present method was
fully validated using the total error approach.45–47
The b risk for the conﬁdence interval has been set to 5%,
and the ± k acceptance limits have been set to 10%. Accuracy
proﬁles and validation parameters have been computed with
e.noval software V2.0 (Arlenda, Lie`ge, Belgium).
The pre-validation step of the software allows choosing the
mathematical model that is closest to the response function.
This protocol requires the preparation of two kinds of sam-
ples in two independent ways: calibration standards and vali-
dation standards, as described above.
The experimental plan consisted of three series (reproduc-
ibility conditions) of four repetitions (repeatability conditions)
of analyses.
2.5. GC/MS qualitative analysis
GC/MS analyses were performed using an HP 5890 series II
gas chromatograph (Hewlett–Packard, Agilent, Massy,
France), equipped with a 5971A mass selective detector (Hew-
lett–Packard, Agilent, Massy, France). A 5% phenyl-meth-
ylsiloxane (HP-5MS) capillary column (30 m · 0.25 mm I.D.,
0.25 lm ﬁlm thickness), supplied by Hewlett–Packard (Agi-
lent, Massy, France), was used.Fig. 1 GCMS Total Ion Chromatograms of piperazine derivative mi
MeOPP and 5: MDBP); (B) after silylation (1: BZP-TMS, 2: TFMPP
after acylation (1: BZP-HFB, 2: TFMPP-HFB, 3: mCPP-HFB, 4: MeChromatographic conditions were as follows: initial col-
umn temperature was 90 C for 0.5 min, increased by 20 C/
min to 200 C, then to 280 C at 15 C/min and ﬁnally to
320 C at 20 C/min for 3.67 min. The temperatures of the
injection port and detector were set at 280 and 320 C, respec-
tively. Injection of 1 lL of the sample solution was performed
automatically in splitless mode, and helium (carrier gas) at a
ﬂow rate of 1.0 mL/min. The mass spectrometer was operated
with a ﬁlament current of 300 lA and electron energy of 70 eV
in the electron ionization (EI) mode. Positive ions were ana-
lyzed. Acquisition was carried out in the scan mode, and the
entire mass range from 38 to 650 m/z was collected.
2.6. HPLC/DAD quantitative analysis
Quantitative analysis was performed by high-performance
liquid chromatography, using a liquid chromatograph
equipped with a spectrophotometric diode-array detector
(HPLC-DAD). The study was conducted on a Hewlett–Packard
1050 series HPLC. Chromatographic separation was
carried out on a Thermo Hypersil C18 analytical column
(3 lm · 125 mm · 3 mm i.d.), protected by a Thermo BDS
C18 guard column, in reversed-phase mode, with a mobile
phase gradient. The components of the mobile phase were:
KH2PO4 buffer, 20 mM, adjusted to pH 3.2 with 85% ortho-
phosphoric acid (A) and acetonitrile (B). The ﬂow rate of the
mobile phase was 0.4 mL/min. The total analysis time was
19 min.
The gradient applied was increased from 20% to 40% B
within 12 min, starting from 0 min after injection, then
increased to 70% B in 2 min, and kept at 70% B for 4 min.
Finally, the gradient was raised to 97% B from 18 to 19 min.
The column temperature during the analysis run was main-
tained at 30 C. The volume of injection was 10 lL. The HP
UV-DAD detector operates with a time response of 1 s, peak
width taken >0.05 min and spectra of substances were
recorded from 210 to 400 nm.
3. Results
3.1. GC/MS qualitative analysis
In the applied GC/MS conditions, a good chromatographic
separation for the silylated piperazines was obtained as shown
in Figure 1B. This was not the case for the acylated ones,xture: (A) without derivatization (1: BZP, 2: TFMPP, 3: mCPP, 4:
-TMS, 3: mCPP-TMS, 4: MeOPP-TMS and 5: MDBP-TMS); (C)
OPP-HFB and 5: MDBP-HFB).
Fig. 2 GCMS total ion chromatograms of amphetamine derivative mixture: (A) after silylation (1: Ephedrine-TMS, 2: Ephedrine-
2TMS, 3: Amphetamine-TMS, 4: Methamphetamine-TMS, 5: Ephedrine-2TMS and 6: MBDB-TMS); (B) after acylation (Amphetamine-
HFB, 2: Methamphetamine-HFB, 3: Ephedrine-HFB, 4: Pseudoephedrine-HFB, 5: MDA-HFB, 6: MDMA-HFB, 7: MDEA-HFB and 8:
MBDB-HFB).
Fig. 3 GCMS total ion chromatograms of a mixture containing piperazine and amphetamine derivatives: (A) after silylation (1:
Ephedrine-TMS, 2: Ephedrine-2TMS, 3: Amphetamine-TMS, 4: BZP-TMS, 5: TFMPP-TMS, 6: Methamphetamine-TMS, 7: Ephedrine-
2TMS, 8: MBDB-TMS, 9: mCPP-TMS, 10: MeOPP-TMS and 11: MDBP-TMS); (B) after acylation (1: Amphetamine-HFB, 2:
Methamphetamine-HFB, 3: Ephedrine-HFB, 4: Pseudoephedrine-HFB, 5: MDA-HFB, 6: BZP-HFB, 7: TFMPP-HFB, 8: MDMA-HFB,
9: MDEA-HFB, 10: MBDB-HFB, 11: mCPP-HFB, 12: MeOPP-HFB and 13: MDBP-HFB).
Table 1 Retention times (RT), mass spectra (m/z) and the limits of detection (LODs) for ﬁve piperazine derivatives.
Substance RT (min) m/z LOD (lg/mL)
Without derivatization BZP 4.454 91;56;134;176 100.00
TFMPP 4.647 188;56;95;172;145;230 93.50
mCPP 6.045 154;56;75;11;138;196 71.50
MeOPP 6.143 150;56;92;120;135;192 73.00
MDBP 6.866 135;56;85;178;164;220 116.00
After silylation BZP-TMS 5.733 102;59;116;157;233;248 0.70
TFMPP-TMS 5.905 302;59;73;101;128;173 0.75
mCPP-TMS 7.283 128;59;73;101;;226;268 0.80
MeOPP-TMS 7.370 264;59;73;101;135;162 0.80
MDBP-TMS 8.039 135;59;73;102;;157;292 1.00
After acylation BZP-HFB 6.147 91;56;146;175;281;372 0.50
TFMPP-HFB 6.156 200;56;69;145;173;426 0.60
mCPP-HFB 7.446 392;56;69;139;166;195 0.60
MeOPP-HFB 7.525 388;56;69;135;191 0.80
MDBP-HFB 8.364 135;56;77;281;416 0.90
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94 Y. Boumrah et al.where a total co-elution between BZP and TFMPP was
observed (Figure 1C). The derivatizing agents, acting on differ-
ent sites (a mobile hydrogen for the silylation reaction, primary
amine moiety for acylation) generate chemical structures that
can easily be differentiated by mass spectrometry.Fig. 5 HPLC-UV/DAD chromatograms of piperazine derivative mi
TP, detection at 210.4 nm [1: BZP; 2: MDBP; 3: MeOPP; 4: P-TP; 5: m
detection at 230.4 nm [1: BZP; 2: MDBP; 3: MeOPP; 4: MDMA; 5: m
Fig. 4 GCMS total ion chromatogram of a mixture containing pipera
(1) Amphetamine-HFB, (2) Ephedrine-TMS, (3) Methamphetamine-H
2TMS, (7) Ephedrine-2TMS, (8) Pseudoephedrine-HFB-TMS, (9) Am
TMS, (13) Methamphetamine-TMS, (14) BZP-HFB, (15) MDMA-HF
mCPP-TMS, (20) MeOPP-TMS, (21) mCPP-HFB, (22) MeOPP-HFB
Table 2 Integration criteria of the piperazine derivatives.
BZP BZP
Dosing range (mg/L) 2–30 30–100
Wave length (nm) 210.4 254.4
Criteria of integration Height AreaMass spectra are very speciﬁc, and allow unambiguous
identiﬁcation on the basis of major ions with m/z values given
in Table 1.
The limits of detection (LODs) for the GC/MS method
were determined. A concentration causing a detector signal
three times greater than the noise (S/N= 3) was accepted asxture: (A) Piperazine derivative mixture with internal standard P-
CPP and 6: TFMPP]; (B) Piperazines mixed with amphetamines,
CPP and 6: TFMPP].
zines and amphetamines after a combined silylation and acylation:
FB, (4) Ephedrine-HFB, (5) Pseudoephedrine-HFB, (6) Ephedrine-
phetamine-TMS, (10) MDA-HFB, (11) BZP-TMS, (12) TFMPP-
B, (16) MDEA-HFB, (17) MBDB-TMS, (18) MBDB-HFB, (19)
and (23) MDBP-HFB.
MDBP MeOPP mCPP TFMPP
2–100 10–100 10–100 10–100
286.4 230.4 210.4 210.2
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concentration range of 0.5–1.0 mg/L after acylation or silyla-
tion and 71.5–100 mg/L without derivatization.
The acylated amphetamines were well separated and identi-
ﬁed (Figure 2B), whereas, this was not the case with the silylat-
ed ones (Figure 2A). The mixture containing the studied
piperazine and amphetamine derivatives is then well identiﬁed
after HFBA-derivatization and the target components are well
separated except those of BZP and TFMPP as shown in
Figure 3B. For this reason, a combined silylation–acylation
derivatization protocol was carried out and the results show
a better identiﬁcation and a total separation of all the target
components as shown in Figure 4.
3.2. HPLC/DAD validated method for quantitative analysis
Typical HPLC/DAD chromatograms of the piperazine deriva-
tives and of the piperazines mixed with amphetamine deriva-
tives are shown in Figure 5. The achieved separation was
satisfactory in both analyses with a small co-elution between
BZP and MDBP. The ﬁve piperazine derivatives are well sep-
arated from the amphetamines, especially from MDMA which
is the most encountered substance in an admixture with the
piperazine derivatives.
Because of the BZP-MDBP co-elution, the quantiﬁcation
of BZP has to be carried out for lower concentrations by con-
sidering the peak height at the absorption maximum
(210.4 nm), then by considering the area for upper concentra-
tions, at 254.4 nm (Table 2). However, these two substances
are rarely simultaneously present in the same tablet.
3.3. Method validation
A weighted (1/X2) quadratic regression model was selected for
the quantitative determination of BZP from 2 to 30 mg/L and
a linear regression through 0 ﬁtted with the level 100 model
from 30 to 100 mg/L. A linear regression through 0 ﬁtted with
the level 100 was selected for both MBDP and TFMPP from 2
to 100 mg/L. For mCPP and MeOPP, a linear regression
model was selected. The validation results for the response
functions in the present study are presented in Table 3.
According to the acceptance criteria (acceptance lim-
its ± 10%, expectation tolerance limits of 90%), the selected
method was shown to be sufﬁciently accurate since the bias
did not exceed the value of 15% (Table 3). In addition, no sys-
tematic bias was observed, and this conﬁrms the absence of a
matrix effect.
The relative standard deviation for both repeatability and
intermediate precision was between 0.37% and 7.18%.
3.3.1. Accuracy
The upper and the lower b-expectation tolerance limits
expressed in mg/L are presented in Table 4 as a function of
the introduced amounts. As can be seen from these results,
the tolerance limits did not exceed the acceptation limits for
all concentration levels tested: the proposed method is accurate
in the range from 8.5 to 100 mg/L for BZP, 17.5 to 100 mg/L
for MDBP, 10 to 100 mg/L for both MeOPP and mCPP piper-
azines and 6 to 100 mg/L for TFMPP. Furthermore, the risk of
having future assay results exceeding the 10% limits of the tar-
geted amount is strictly controlled.48–52
96 Y. Boumrah et al.The linearity of the analytical method was tested. The
regression equations are presented in Table 5.
Limits of quantiﬁcation are obtained by calculating the
smallest and highest concentration beyond which the accuracy
limits or b-expectation limits exceed the acceptance limits. The
results are presented in Table 5.
4. Discussion
The use of accuracy proﬁles for the validation based on total
error concept is compliant with the fundamental demands of
the ISO/CEI 17025 standard, for example validation and
determination of measurement uncertainty. This method is
based on the determination of conﬁdence interval of measure-Table 4 Validation results (trueness, precision, and accuracy) f
derivatives.
BZP BZP MDBP MeOPP m
Trueness (k = 3, m = 11, n = 4) Relative bias (%)
2 0.6 – 6.3 – –
10 1.0 – 3.0 1.5 1.2
20 0.2 – 0.4 1.4 1.3
30 0.1 1.1 4.4 2.9 2.0
40 – 0.2 2.7 2.9 2.2
50 – 1.5 1.0 1.2 0.9
60 – 0.9 2.0 1.7 1.8
70 – 1.0 1.5 2.1 1.4
80 – 1.3 1.4 1.2 1.1
90 – 1.6 1.5 1.1 0.8
100 – 2.3 1.6 2.4 0.5
Precision (k = 3, m = 11, n = 4) Repeatability (RSD,%)
2 5.2 – 4.7 – –
10 1.6 – 2.0 2.1 1.5
20 3.7 – 1.9 1.9 1.3
30 1.7 1.3 2.1 1.5 1.6
40 – 0.5 0.6 0.6 0.4
50 – 0.9 0.7 1.0 0.7
60 – 0.8 0.9 1.0 0.7
70 – 0.7 0.7 1.6 0.6
80 – 0.7 0.4 0.5 0.6
90 – 0.8 0.4 0.6 0.6
100 – 0.8 0.6 0.6 0.7
Accuracy (k= 3, m= 11, n= 4) b-expectation tolerance limits (ng
BZP BZP
2 [01.7, 02.3] –
10 [09.1, 10.6] –
20 [18.6, 21.4] –
30 [27.2, 32.7] [28.8, 30.5]
40 – [38.4, 41.4]
50 – [48.4, 50.1]
60 – [58.1, 60.8]
70 – [67.5, 71.1]
80 – [77.9, 80.1]
90 – [85.3, 91.7]
100 – [96.1, 99.3]
Number of replicates (n).
Number of amount levels (m).
Number of series (Day) (k).
Relative standard deviation (RSD).ments, with a risk b. This interval, also called b expectation
interval, is computed from accuracy and intermediate preci-
sion. For each concentration level included in the experiment,
the standard deviation of intermediate precision is calculated
by adding the repeatability variance to the inter-series variance
(SIF
2 = SR
2 + SIS
2 ). The graphical representation of these b
expectation tolerance limits builds up the accuracy proﬁle of
the quantiﬁcation method.
From a practical point of view, the validation decision is
based on the graphical comparison of the accuracy proﬁle
obtained previously with the acceptance limits ± k that are
set prior to the beginning of the experiment. The acceptance
limits correspond to the maximal uncertainty of measurement
that is accepted for the results obtained by the analyticalor the HPLC/DAD quantitative determination of piperazine
CPP TFMPP BZP BZP MDBP MeOPP mCPP TFMPP
Recovery (%)
6.6 99.4 – 93.7 – – 106.6
2.3 99.0 – 97.0 101.5 101.2 102.3
1.7 100.2 – 99.6 101.4 101.3 101.7
3.0 99.9 98.9 104.4 102.9 102.0 103.0
2.9 – 99.8 102.7 102.9 102.2 102.9
13 – 98.5 101.0 101.2 100.9 101.3
2.1 – 99.0 102.0 101.7 101.8 102.1
2.0 – 99.0 101.5 102.1 101.4 102.0
1.6 – 98.8 101.4 101.2 101.1 101.6
1.6 – 98.4 101.5 101.1 100.8 101.6
1.6 – 97.7 101.6 102.4 100.5 101.6
Intermediate precision (RSD,%)
4.3 7.2 – 5.9 – – 4.3
1.6 3.0 – 3.8 2.2 2.2 1.6
1.6 3.7 – 3.5 1.9 1.3 1.6
17 3.4 1.5 2.0 1.9 1.9 1.7
0.4 – 1.3 2.0 1.0 1.2 1.1
0.5 – 0.9 2.0 1.6 1.3 1.2
0.7 – 1.0 1.3 1.0 1.0 1.1
0.7 – 1.0 1.4 1.6 0.8 1.2
0.7 – 0.7 1.5 1.2 1.3 1.3
0.6 – 1.2 1.8 1.4 1.4 1.8
0.8 – 0.8 1.4 1.2 1.0 1.5
)
MDBP MeOPP mCPP TFMPP
[01.6, 02.1] – – [01.9, 02.3]
[08.7, 10.6] [09.8, 10.7] [09.6, 10.6] [09.8, 10.4]
[18.2, 21.7] [19.7, 21.2] [19.9, 20.8] [19.6, 20.8]
[29.4, 31.7] [30.0, 32.3] [29.6, 32.0] [29.7, 31.6]
[38.4, 43.6] [40.5, 42.5] [39.7, 42.7] [39.5, 42.2]
[47.4, 53.3] [49.1, 53.1] [49.1, 52.5] [48.6, 52.1]
[59.1, 62.8] [60.5, 62.7] [60.2, 62.9] [59.2, 62.5]
[68.3, 73.4] [70.1, 74.2] [70.4, 72.8] [68.7, 73.0]
[77.2, 84.7] [79.3, 84.4] [78.5, 84.3] [77.9, 83.5]
[85.9, 96.3] [88.4, 95.6] [87.8, 95.0] [86.1, 95.4]
[97.5, 105.2] [99.4, 105.4] [99.0, 103.7] [96.8, 104.9]
Table 5 Validation results (linearity, limits of quantiﬁcation) for the quantitative determination of piperazine derivatives.
BZP BZP MDBP MeOPP mCPP TFMPP
Linearity (k = 3,m = 11, n = 4)
Range (ng) 8.545–30 30–100 17.54–100 10–100 10–100 5.95–100
Slope 1.0010 0.9746 1.0170 1.0160 1.0060 1.0140
Intercept 0.04276 0.74460 0.04606 0.09157 0.3459 0.2102
r2 0.9970 0.9991 0.9992 0.9992 0.9994 0.9994
Limits of quantiﬁcation (k = 3,m = 11, n = 4)
Lower limit of quantiﬁcation (lg/mL) 8.545 30 17.54 10.10 10 5.95
Upper limit of quantiﬁcation (lg/mL) 30 100 100 100 100 100
Number of replicates (n).
Number of amount levels (m).
Number of series (Day) (k).
Figure 6 Accuracy proﬁles of piperazine derivatives (amount in mg/L): (1) Accuracy proﬁle of BZP from 02 to 30 mg/L using a weighted
(1/X2) quadratic regression model; (2) Accuracy proﬁle of BZP from 30 to 100 mg/L using a linear regression through 0 ﬁtted with the level
100 only model; (3) Accuracy proﬁle of MDBP from 02 to 100 mg/L using a linear regression through 0 ﬁtted with the level 100 only
model; (4) Accuracy proﬁle of MeOPP from 10 to 100 mg/L using a linear regression model; (5) Accuracy proﬁle of mCPP from 10 to
100 mg/L using a linear regression model; (6) Accuracy proﬁle of TFMPP from 02 to 100 mg/L using a linear regression through 0 ﬁtted
with the level 100 only model. The plain line is the relative bias, the dashed lines are the b-expectation tolerance limits and the dotted lines
represent the acceptance limits (10%). The dots represent the relative back-calculated concentrations and are plotted with respect to their
targeted concentration.
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istic constraints of the domain or activity in which the dosing
will be implemented. For example, in forensic toxicology the
limit is ± k= 40%. For the analysis of illicit substances in
seized material described in this case,±k of 10% was chosen.
The overall performance of the method described in this
paper is much better than expected, as can be seen in Fig. 6
for MeOPP and mCPP. Moreover, during the pre-validation
step, the best mathematical model of response function which
is chosen is the one which gives the best accuracy index, or the
best analytical performance in terms of LOQ and uncertainty
measurement.5. Conclusions
TheGC/MSmethod developed in this work has allowed the sep-
aration and the identiﬁcation of a large number of piperazine
and amphetamine-type substances. The HPLC/DAD quantita-
tive method is fully validated following the concept of total
error, by means of accuracy proﬁles. This graphical approach
allows to study in a global way accuracy and intermediate repro-
ducibility, and eventually to easily set LOQ and dosing range.
The quantitative method has shown to be linear within the
adopted ranges for all the studied piperazines. Furthermore,
98 Y. Boumrah et al.both qualitative and quantitative methods can be useful to lab-
oratories for performing routine analyses of seizedmaterial con-
taining piperazine and amphetamine-type substances.
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